further investigation, but this report provides evidence that iron overload can occur in AMD not only in the RPE and Bruch’s membrane but also in the neurosensory retina. Because iron can cause oxidative stress, it may be toxic to both the RPE and photoreceptors, cells in which cell death leads to blindness in AMD. Iron chelation therapy may one day prove useful in the prevention of vision loss...

PROPOSAL The World Health Organization Model List of Essential Medicines and Model Formulary 2010 list deferoxamine (DFO) as the treatment of choice for both acute and chronic iron poisoning. The Model Formulary currently does not designate any orally administered agents for the chelation of iron. It is proposed that deferasirox be considered the oral chelator of choice in the treatment of chro...

Tripodal hexadentate hydroxypyridin-4-ones are increasingly utilised as iron(III) and gallium(III) ligands, their attachment to proteins being particularly useful for positron emission tomography (PET). A widely studied tripodal ligand NTA(BuHP)3, which is reported to form 1:1 iron(III) and gallium(III) complexes in aqueous, media forms 2:2 complexes under physiological conditions. This importa...

Iron chelators belonging to three distinct chemical families were assessed in terms of their physicochemical properties and the kinetics of iron chelation in solution and in two biological systems. Several hydroxypyridinones, reversed siderophores, and desferrioxamine derivatives were selected to cover agents with different iron-binding stoichiometry and geometry and a wide range of lipophilici...

In this issue of Neuron, Kaur et al. demonstrate that iron chelation by ferritin transgene or the metal chelator clioquinol prevent oxidative damage and MPTP toxicity in mice. This raises the issue of specific iron chelators or clioquinol for control of oxidative damage in Parkinson's, Alzheimer's, and other neurodegenerative diseases, but not without safety concerns.

• Background Patients with haemoglobinopathies, such as β-thalassaemia and sickle cell disease (SCD), and other transfusion-dependent anaemias usually require regular blood transfusions which leads to iron accumulation in the heart and liver. Iron chelation therapy is used to prevent iron toxicity but requires close monitoring of body iron levels to ensure optimal dosage and avoid potential adv...

 Background Patients with haemoglobinopathies, such as β-thalassaemia and sickle cell disease (SCD), and other transfusion-dependent anaemias usually require regular blood transfusions which leads to iron accumulation in the heart and liver. Iron chelation therapy is used to prevent iron toxicity but requires close monitoring of body iron levels to ensure optimal dosage and avoid potential adv...

BACKGROUND In transfusional siderosis, the iron binding capacity of plasma transferrin is often surpassed, with concomitant generation of non-transferrin-bound iron. Although implicated in tissue siderosis, non-transferrin-bound iron modes of cell ingress remain undefined, largely because of its variable composition and association with macromolecules. Using fluorescent tracing of labile iron i...

Recently, we reported that heme binds to tumor suppressor p53 protein (TP53, best known as p53) and promotes its nuclear export and cytosolic degradation, whereas iron chelation stabilizes p53 protein and suppresses tumors in a p53-dependent manner. This not only provides mechanistic insights into tumorigenesis associated with iron excess, but also helps guide the administration of chemotherapy...

We read the publication entitled “Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation” with great interest [1]. As summarized by Atilla et al. [1], “Organ dysfunction due to iron overload may cause high mortality rates and therefore a sufficient iron chelation therapy is recommended”. We would like to share the experience from our settings where ...